Share Email Print
cover

Proceedings Paper

Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration
Author(s): Leilei Zhang; Jeff Xu; Jiwei Huang; Cynthia Roberts; Ronald Xu
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Bevacizumab (Avastin) has been used as one of the anti-VEGF therapies to manage neovascular age-related macular degeneration (AMD). The drug delivery system for bevacizumab needs to be improved in order to decrease the frequency of injection and reduce the adverse effects. In our study, bevacizumab was conjugated with poly (lactic-co-glycolic acid) (PLGA) microbubbles by activating carboxyl functional groups. The averaged size of microbubbles was estimated 1.055±0.258μm, allowing for ultrasound guided drug delivery. The binding efficiency between bevacizumab and microbubbles was evaluated in an enzyme-linked immunosorbent assay plate. The test results demonstrated the potential of using PLGA microbubbles to deliver bevacizumab with imaging guidance.

Paper Details

Date Published: 2 March 2010
PDF: 8 pages
Proc. SPIE 7550, Ophthalmic Technologies XX, 75501P (2 March 2010); doi: 10.1117/12.841932
Show Author Affiliations
Leilei Zhang, The Ohio State Univ. (United States)
Jeff Xu, The Ohio State Univ. (United States)
Jiwei Huang, The Ohio State Univ. (United States)
Cynthia Roberts, The Ohio State Univ. (United States)
Ronald Xu, The Ohio State Univ. (United States)


Published in SPIE Proceedings Vol. 7550:
Ophthalmic Technologies XX
Fabrice Manns; Per G. Söderberg; Arthur Ho, Editor(s)

© SPIE. Terms of Use
Back to Top